9 December 2025
MMV, a not-for-profit public-private partnership, was established as a foundation in Switzerland. It was created to discover, develop and deliver new, effective and affordable drugs for malaria in collaboration with public and private partners. MMV was one of the first product development partnerships (PDPs) and is a leader in terms of antimalarial drug research and development. A sister organization, the PATH Malaria Vaccines Initiative (MVI), focuses on malaria vaccine discovery and development.
MMV was launched on 3 November 1999, with initial seed finance of US$ 4 million from the Government of Switzerland, UK Department for International Development, the Government of the Netherlands, The World Bank and Rockefeller Foundation.
Over the past decade MMV has successfully worked with more than 260 partners in almost 50 countries from the private sector, from the public sector, from NGOs and non profit organizations, as well as from clinical centres in endemic countries.
MMV’s portfolio focuses on delivering new antimalarial medicines that are affordable, accessible and appropriate for use in malariaendemic areas. Each medicine must provide significant benefit compared to the current gold standard treatment and be active against all known resistant strains of the parasite. Specifically, the goal is to develop products that will provide a range of benefits including:
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development.
Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.
Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries.
